NASDAQ:ATHE Alterity Therapeutics (ATHE) Stock Price, News & Analysis $5.01 -0.05 (-0.99%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$4.99 -0.02 (-0.50%) As of 08/1/2025 07:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Alterity Therapeutics Stock (NASDAQ:ATHE) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Alterity Therapeutics alerts:Sign Up Key Stats Today's Range$4.87▼$5.1550-Day Range$3.84▼$6.5552-Week Range$1.00▼$7.00Volume45,942 shsAverage Volume205,931 shsMarket Capitalization$44.44 millionP/E RatioN/ADividend YieldN/APrice Target$12.00Consensus RatingModerate Buy Company Overview Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy advance; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia. Read More Alterity Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks35th Percentile Overall ScoreATHE MarketRank™: Alterity Therapeutics scored higher than 35% of companies evaluated by MarketBeat, and ranked 730th out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus RatingAlterity Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Amount of Analyst CoverageAlterity Therapeutics has received no research coverage in the past 90 days.Read more about Alterity Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Book Value per Share RatioAlterity Therapeutics has a P/B Ratio of 4.82. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Alterity Therapeutics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.06% of the float of Alterity Therapeutics has been sold short.Short Interest Ratio / Days to CoverAlterity Therapeutics has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Alterity Therapeutics has recently increased by 20.33%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAlterity Therapeutics does not currently pay a dividend.Dividend GrowthAlterity Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted1.06% of the float of Alterity Therapeutics has been sold short.Short Interest Ratio / Days to CoverAlterity Therapeutics has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Alterity Therapeutics has recently increased by 20.33%, indicating that investor sentiment is decreasing significantly. News and Social Media1.1 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 2 news articles for Alterity Therapeutics this week, compared to 0 articles on an average week.Search Interest1 people have searched for ATHE on MarketBeat in the last 30 days. MarketBeat Follows1 people have added Alterity Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Alterity Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders38.80% of the stock of Alterity Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 2.14% of the stock of Alterity Therapeutics is held by institutions.Read more about Alterity Therapeutics' insider trading history. Receive ATHE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Alterity Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ATHE Stock News HeadlinesAppendix 4C – Q4 FY25 Quarterly Cash Flow ReportJuly 30 at 7:25 AM | globenewswire.comAlterity Therapeutics Reports Positive Topline Data from Open-Label Phase 2 Clinical Trial of ATH434 in Multiple System AtrophyJuly 28, 2025 | globenewswire.comThis Crypto Is Set to Explode in JanuaryBillions Flowing Into Crypto (Here’s Where It’s Going!) Institutional money is flooding into crypto... Discover which coins they’re buying at the Crypto Hedge Fund Summit, before prices catch up. | Crypto 101 Media (Ad)Alterity Therapeutics Ltd. ADR (ATHE) Stock Price Today - WSJJuly 26, 2025 | wsj.comAlterity Therapeutics Announces Publication on Novel MRI Endpoint from the bioMUSE Natural History StudyJuly 24, 2025 | globenewswire.comAlterity Therapeutics to Provide Corporate Update in Fireside ChatJune 23, 2025 | globenewswire.comAlterity Therapeutics highlighted at MSA CongressMay 14, 2025 | uk.investing.comAlterity Therapeutics Prominently Featured at the International MSA CongressMay 12, 2025 | globenewswire.comSee More Headlines ATHE Stock Analysis - Frequently Asked Questions How have ATHE shares performed this year? Alterity Therapeutics' stock was trading at $3.31 at the beginning of 2025. Since then, ATHE stock has increased by 51.4% and is now trading at $5.01. When did Alterity Therapeutics' stock split? Shares of Alterity Therapeutics reverse split before market open on Monday, January 9th 2023.The 1-10 reverse split was announced on Monday, January 9th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, January 9th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. Who are Alterity Therapeutics' major shareholders? Top institutional investors of Alterity Therapeutics include Greenleaf Trust (0.19%). How do I buy shares of Alterity Therapeutics? Shares of ATHE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Alterity Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Alterity Therapeutics investors own include NVIDIA (NVDA), GE Aerospace (GE), Broadcom (AVGO), Meta Platforms (META), Dorian LPG (LPG), CymaBay Therapeutics (CBAY) and Company Calendar Today8/02/2025Next Earnings (Estimated)8/04/2025Fiscal Year End6/30/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ATHE CIK1131343 Webwww.alteritytherapeutics.com Phone(139) 349-4906Fax61-3-9348-0377Employees10Year FoundedN/APrice Target and Rating Average Price Target for Alterity Therapeutics$12.00 High Price Target$12.00 Low Price Target$12.00 Potential Upside/Downside+139.5%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio3.84 Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.04 per share Price / Book4.82Miscellaneous Outstanding Shares8,870,000Free Float5,427,000Market Cap$44.44 million OptionableNot Optionable Beta0.66 Social Links 10 Stocks Set to Soar in Summer 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free Report This page (NASDAQ:ATHE) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alterity Therapeutics Limited - Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Alterity Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.